H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Moody, M Anthony ^a   Zhang, Ruijun ^a   Walter, Emmanuel B ^a   Woods, Christopher W ^a,b   Ginsburg, Geoffrey S ^a   McClain, Micah T ^a,b   Denny, Thomas N ^a   Chen, Xi ^a   Munshaw, Supriya ^a   Marshall, Dawn J ^a   Whitesides, John F ^a   Drinker, Mark S ^a   Amos, Joshua D ^a   Gurley, Thaddeus C ^a   Eudailey, Joshua A ^a   Foulger, Andrew ^a   DeRosa, Katherine R ^a   Parks, Robert ^a   Meyerhoff, R Ryan ^a   Yu, Jae Sung ^a   Kozink, Daniel M ^a   Barefoot, Brice E ^a   Ramsburg, Elizabeth A ^a   Khurana, Surender ^c   Golding, Hana ^c   Vandergrift, Nathan A ^a   Alam, S Munir ^a   Tomaras, Georgia D ^a   Kepler, Thomas B ^a   Kelsoe, Garnett ^a   Liao, Hua Xin ^a   Haynes, Barton F ^a   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; INFLUENZA VIRUS HEMAGGLUTININ;

ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; INFLUENZA A (H3N2); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MALE; PLASMA CELL; VACCINATION; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANTIBODY SPECIFICITY; BIOSYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; INFLUENZA; ISOLATION AND PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURFACE PLASMON RESONANCE; VIROLOGY;

TIPULA IRIDESCENT VIRUS;

ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURFACE PLASMON RESONANCE;

EID: 80054780343     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025797     Document Type: Article

References (60)

1. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, et al. (2004) Influenza-associated hospitalizations in the United States. JAMA 292: 1333-1340.
2. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-186.
3. Anonymous, (2009) Update: influenza activity-United States, April-August 2009. MMWR Morb Mortal Wkly Rep 58: 1009-1012.
4. Johnson NP, Mueller J, (2002) Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 76: 105-115.
5. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, et al. (2009) Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 58: 1-52.
6. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, et al. (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453: 667-671.
7. Knossow M, Skehel JJ, (2006) Variation and infectivity neutralization in influenza. Immunology 119: 1-7.
8. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143-155.
9. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
10. Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, et al. (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A 105: 5986-5991.
11. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273.
12. Corti D, Suguitan AL Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, et al. (2010) Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120: 1663-1673.
13. Zaas AK, Chen M, Varkey J, Veldman T, Hero AO 3rd, et al. (2009) Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe 6: 207-217.
14. Liao HX, Levesque MC, Nagel A, Dixon A, Zhang R, et al. (2009) High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods 158: 171-179.
15. Renfrey S, Watts A, (1994) Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom. Vaccine 12: 747-752.
16. Davenport FM, Hennessy AV, Francis T, (1953) Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. The Journal of experimental medicine 98: 641-656.
17. Fazekas de St G, Webster RG, (1966) Disquisitions on Original Antigenic Sin. II. Proof in lower creatures. J Exp Med 124: 347-361.
18. Fazekas de St G, Webster RG, (1966) Disquisitions of Original Antigenic Sin. I. Evidence in man. J Exp Med 124: 331-345.
19. Webster RG, (1966) Original antigenic sin in ferrets: the response to sequential infections with influenza viruses. J Immunol 97: 177-183.
20. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208: 181-193.
21. Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, et al. (2008) Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 455: 532-536.
22. Kashyap AK, Steel J, Rubrum A, Estelles A, Briante R, et al. (2010) Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries. PLoS Pathog 6: e1000990.
23. Forgie SE, Keenliside J, Wilkinson C, Webby R, Lu P, et al. (2011) Swine outbreak of pandemic influenza A virus on a Canadian research farm supports human-to-swine transmission. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 52: 10-18.
24. Lau LL, Cowling BJ, Fang VJ, Chan KH, Lau EH, et al. (2010) Viral shedding and clinical illness in naturally acquired influenza virus infections. The Journal of Infectious Diseases 201: 1509-1516.
25. Katz JM, Lim W, Bridges CB, Rowe T, Hu-Primmer J, et al. (1999) Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. The Journal of Infectious Diseases 180: 1763-1770.
26. Anonymous, (2009) Update on influenza A (H1N1) 2009 monovalent vaccines. MMWR Morb Mortal Wkly Rep 58: 1100-1101.
27. Whittle J, Zhang R, Khurana S, King LR, Manischewitz J, et al. (2011) Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A in press.
28. De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, et al. (2005) Universal influenza A vaccine: optimization of M2-based constructs. Virology 337: 149-161.
29. Schotsaert M, De Filette M, Fiers W, Saelens X, (2009) Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 8: 499-508.
30. Kwong PD, Wilson IA, (2009) HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 10: 573-578.
31. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, et al. (2010) Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329: 1060-1064.
32. Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, et al. (2010) Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2: 15ra15.
33. McKean D, Huppi K, Bell M, Staudt L, Gerhard W, et al. (1984) Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. Proc Natl Acad Sci U S A 81: 3180-3184.
34. Clarke SH, Huppi K, Ruezinsky D, Staudt L, Gerhard W, et al. (1985) Inter- and intraclonal diversity in the antibody response to influenza hemagglutinin. J Exp Med 161: 687-704.
35. Clarke S, Rickert R, Wloch MK, Staudt L, Gerhard W, et al. (1990) The BALB/c secondary response to the Sb site of influenza virus hemagglutinin. Nonrandom silent mutation and unequal numbers of VH and Vk mutations. J Immunol 145: 2286-2296.
36. Sangster MY, Topham DJ, D'Costa S, Cardin RD, Marion TN, et al. (2000) Analysis of the virus-specific and nonspecific B cell response to a persistent B-lymphotropic gammaherpesvirus. J Immunol 164: 1820-1828.
37. Krause JC, Tumpey TM, Huffman CJ, McGraw PA, Pearce MB, et al. (2010) Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol 84: 3127-3130.
38. Clarke SH, Staudt LM, Kavaler J, Schwartz D, Gerhard WU, et al. (1990) V region gene usage and somatic mutation in the primary and secondary responses to influenza virus hemagglutinin. J Immunol 144: 2795-2801.
39. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3: e3942.
40. Sasso EH, Johnson T, Kipps TJ, (1996) Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number. J Clin Invest 97: 2074-2080.
41. Pape KA, Taylor JJ, Maul RW, Gearhart PJ, Jenkins MK, (2011) Different B cell populations mediate early and late memory during an endogenous immune response. Science 331: 1203-1207.
42. Wang TT, Tan GS, Hai R, Pica N, Petersen E, et al. (2010) Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 6: e1000796.
43. Laurie KL, Carolan LA, Middleton D, Lowther S, Kelso A, et al. (2010) Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis 202: 1011-1020.
44. Wang TT, Tan GS, Hai R, Pica N, Ngai L, et al. (2010) Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 107: 18979-18984.
45. Steel J, Lowen AC, Wang T, Yondola M, Gao Q, et al. (2010) Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1.
46. Dal Porto JM, Haberman AM, Kelsoe G, Shlomchik MJ, (2002) Very low affinity B cells form germinal centers, become memory B cells, and participate in secondary immune responses when higher affinity competition is reduced. J Exp Med 195: 1215-1221.
47. Shih TA, Meffre E, Roederer M, Nussenzweig MC, (2002) Role of BCR affinity in T cell dependent antibody responses in vivo. Nat Immunol 3: 570-575.
48. Jackson GG, Dowling HF, Spiesman IG, Boand AV, (1958) Transmission of the common cold to volunteers under controlled conditions. I. The common cold as a clinical entity. AMA Arch Intern Med 101: 267-278.
49. Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, et al. (2009) Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc 4: 372-384.
50. Ewing B, Green P, (1998) Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res 8: 186-194.
51. Ewing B, Hillier L, Wendl MC, Green P, (1998) Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 8: 175-185.
52. Kepler TB, Sample C, Hudak K, Roach J, Haines A, et al. (2010) Chiropteran types I and II interferon genes inferred from genome sequencing traces by a statistical gene-family assembler. BMC Genomics 11: 444.
53. Smith TF, Waterman MS, (1981) Identification of common molecular subsequences. J Mol Biol 147: 195-197.
54. Volpe JM, Cowell LG, Kepler TB, (2006) SoDA: implementation of a 3D alignment algorithm for inference of antigen receptor recombinations. Bioinformatics 22: 438-444.
55. Felsenstein J, (2005) PHYLIP (Phylogeny Inference Package). 3.6 ed Seattle, WA distributed by the author, Department of Genome Sciences, University of Washington.
56. Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, et al. (2009) Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol 83: 8925-8937.
57. Alam SM, Scearce RM, Parks RJ, Plonk K, Plonk SG, et al. (2008) Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J Virol 82: 115-125.
58. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, et al. (2008) Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82: 12449-12463.
59. Alam SM, McAdams M, Boren D, Rak M, Scearce RM, et al. (2007) The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 178: 4424-4435.
60. Cottey R, Rowe CA, Bender BS, (2001) Influenza virus. Curr Protoc Immunol Chapter 19: Unit 19 11.